firategrast   Click here for help

GtoPdb Ligand ID: 11486

Synonyms: SB-683699 | SB683699
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Firategrast (SB-683699) is an orally bioavailable, short-acting small molecule α4-integrin antagonist. It was designed to reduce α4β1/α4β7 integrin-mediated trafficking of lymphocytes into the central nervous system (CNS). Anti-α4-integrin natalizumab is currently approved to treat MS, but its long half-life is problematic, and it has to be administered by infusion. This short acting small molecule was developed as an alternative to antibody therapy.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 12
Topological polar surface area 94.09
Molecular weight 499.18
XLogP 5
No. Lipinski's rules broken 2
Click here for help
Canonical SMILES CCOCc1cc(OC)c(c(c1)OC)c1ccc(cc1)C[C@@H](C(=O)O)NC(=O)c1c(F)cccc1F
Isomeric SMILES CCOCc1cc(OC)c(c(c1)OC)c1ccc(cc1)C[C@@H](C(=O)O)NC(=O)c1c(F)cccc1F
InChI InChI=1S/C27H27F2NO6/c1-4-36-15-17-13-22(34-2)24(23(14-17)35-3)18-10-8-16(9-11-18)12-21(27(32)33)30-26(31)25-19(28)6-5-7-20(25)29/h5-11,13-14,21H,4,12,15H2,1-3H3,(H,30,31)(H,32,33)/t21-/m0/s1
No information available.
Summary of Clinical Use Click here for help
Phase 2 clinical trials of firategrast in MS and Crohn's disease have been completed.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT00395317 Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Multiple Sclerosis (MS) Phase 2 Interventional GlaxoSmithKline 2
NCT00101946 Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease Phase 2 Interventional GlaxoSmithKline